News

Schrödinger and Bayer announced a five-year technology alliance to develop a comprehensive de novo design solution with the objective to accelerate the discovery of innovative…
Read More...

Immunic, Inc. announced that its subsidiary, Immunic AG, under the terms of its existing option and license agreement with Daiichi Sankyo Co., Ltd. (hereinafter, Daiichi Sankyo), has…
Read More...

Catabasis Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company, and Duchenne UK, a charity that seeks to fund and accelerate treatments and a cure for Duchenne muscular…
Read More...

Avacta Group plc and Daewoong Pharmaceutical Co. Ltd. announced that they have agreed to establish a joint venture in South Korea, and to enter a collaboration and license agreement for…
Read More...

Candel Therapeutics announced that it has acquired all oncolytic and other Herpes Simplex Virus (HSV) based assets from PeriphaGen, Inc., bringing its vector engineering, production…
Read More...

Galecto, the leading developer of galectin modulators for the treatment of fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and cancer, and PharmAkea, Inc., a privately…
Read More...

Curis, Inc. announced that it has entered into an option and license agreement to acquire exclusive, worldwide rights from ImmuNext Inc. (ImmuNext) to develop and commercialize…
Read More...

AstraZeneca announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Farxiga (dapagliflozin) to reduce…
Read More...

Merck, known as MSD outside the United States and Canada, announced an exclusive worldwide research collaboration and license agreement with Taiho Pharmaceutical Co, Ltd., (“Taiho”) and…
Read More...

Bicycle Therapeutics plc announced a second collaboration with Cancer Research UK in which Cancer Research UK will fund and sponsor development of BT7401, a multivalent Bicycle CD137…
Read More...

MiNA Therapeutics, the pioneer in RNA activation therapeutics, announced today the initiation of a research collaboration with AstraZeneca to evaluate small activating RNA ("saRNA")…
Read More...

Veristat, a full-service CRO, announced that it has completed the acquisition of The Clinical Trial Company Ltd. (TCTC Group), a global Contract Research Organization headquartered in…
Read More...

InxMed (Shanghai) Co., Ltd., a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has…
Read More...

ATAI Life Sciences AG announced that it has partnered with Neuronasal Inc., to develop a short-term treatment for mild Traumatic Brain Injury (mTBI) or concussion. Neuronasal's…
Read More...

Pulmatrix, Inc. a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced that it has entered into a research…
Read More...

Abcam plc, a global innovator in life science reagents and tools, is pleased to announce the successful completion of the acquisition of Expedeon's Proteomics and Immunology business,…
Read More...

Charles River Laboratories International announced that it has completed the previously announced acquisition of HemaCare Corporation for approximately $380 million in cash, or $25.40…
Read More...

Leap Therapeutics and BeiGene announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody,…
Read More...

AstraZeneca announced that it has agreed to sell the commercial rights to Arimidex (anastrozole) and Casodex (bicalutamide) in a number of European, African and other countries1 to…
Read More...

PharmaMar and Jazz Pharmaceuticals plc announced that PharmaMar and Jazz Pharmaceuticals Ireland Limited have entered into an exclusive license agreement for lurbinectedin in the United…
Read More...